Best evidence-based treatments for melasma (2026)
By Dr. Mei Chen · Cosmetic Dermatologist & Senior Editor, The Exosome Edit
Updated Jun 2026Melasma is one of the most stubborn pigment problems in dermatology. It looks simple from the outside — brown or gray-brown patches on the cheeks, forehead, upper lip, or jaw — but the underlying biology is messy, and most treatments help for a while and then the patches creep back. This guide walks through what the actual clinical evidence says works, where that evidence is strong, where it's thin or industry-funded, and how to think about building a plan that holds up over years rather than weeks.
Melasma is one of the most stubborn pigment problems in dermatology. It looks simple from the outside — brown or gray-brown patches on the cheeks, forehead, upper lip, or jaw — but the underlying biology is messy, and most treatments help for a while and then the patches creep back. This guide walks through what the actual clinical evidence says works, where that evidence is strong, where it's thin or industry-funded, and how to think about building a plan that holds up over years rather than weeks.
What melasma actually is
Melasma is a chronic disorder of pigmentation. The visible patches come from melanocytes — the cells that make pigment — pumping out too much melanin and dumping it into the surrounding skin. But calling it "extra pigment" undersells it. Research over the last decade shows melasma is not just an epidermal problem. It's a whole-skin problem.
In melasma skin, several things go wrong at once. Sunlight, especially ultraviolet (UV) and high-energy visible light, ramps up pigment production. The basement membrane — the layer that separates the epidermis from the dermis — gets damaged and leaky, so pigment drops down into the dermis where it's much harder to clear. New tiny blood vessels grow in the upper dermis, and these vessels release signals that feed the melanocytes. Mast cells and "senescent" (aged-out) fibroblasts show up and keep the inflammation simmering. There's also a hormonal angle: estrogen and progesterone receptors sit on melanocytes, which is why pregnancy and birth control pills can trigger or worsen it.
This matters for treatment. A cream that only blocks pigment production is fighting one part of a multi-front problem. That's the core reason melasma relapses so often, and why a sober plan layers several approaches and never drops sun protection. For a deeper look at the biology, the two-part review Update on Melasma — Part I: Pathogenesis is the best single source, and the StatPearls Melasma chapter gives a solid clinical overview.
Who gets it
Melasma overwhelmingly affects women — roughly 90% of cases — and it's far more common in people with medium to deep skin tones (Fitzpatrick types III to V), including Hispanic, South Asian, East Asian, Middle Eastern, and African backgrounds. Sun exposure, pregnancy, hormonal contraceptives, and a family history are the main drivers. Men get it too, just less often.
Why it relapses so easily
It helps to understand the relapse problem up front, because it shapes every smart treatment decision. Three features of melasma make it cling on. First, much of the pigment sits in the dermis, below the layer where most creams act, and dermal pigment clears slowly — sometimes over a year or more. Second, the triggers never fully go away: sunlight, hormones, and heat are part of normal life. Third, the underlying skin in a melasma patch is structurally altered (leaky basement membrane, extra blood vessels, aged fibroblasts), so even after the surface looks clear, the machinery that made the pigment is still primed to fire again. That's why "cured" is the wrong frame and "controlled" is the right one.
How treatment is judged
Before the treatments, a quick word on how researchers measure success, because it shapes how you should read claims. Most trials use the MASI or modified MASI (Melasma Area and Severity Index) score, which rates how dark the patches are and how much skin they cover. A bigger drop in MASI means more improvement. The catch: MASI is somewhat subjective, trials are often short (8 to 16 weeks), and many are small. Plenty of melasma studies are also funded by the company selling the product. None of that makes the results worthless, but it means you should weight large, independent, long-follow-up trials more heavily than a glossy 30-person study from a brand.
The single best evidence summary remains the abridged Cochrane review of melasma interventions and the broader evidence-based review in the American Journal of Clinical Dermatology, which together screened thousands of participants across hundreds of trials.
To keep the grading honest throughout this guide, here's a rough quality map of where each major treatment stands. "Strong" means multiple randomized trials or pooled meta-analyses with consistent results; "moderate" means real trial data but smaller, shorter, or less consistent; "weak/mixed" means limited or conflicting evidence, often with industry funding.
| Treatment | Evidence strength | Independent or industry-leaning? | Confidence it helps |
|---|---|---|---|
| Iron-oxide tinted sunscreen | Strong | Mixed, but RCT-backed | High |
| Triple combination cream | Strong | Several independent RCTs | High |
| Hydroquinone alone | Strong | Long clinical track record | High |
| Oral tranexamic acid | Strong (recent) | Mostly independent | High |
| Azelaic acid | Moderate | Independent | Moderate |
| Cysteamine | Moderate | Some industry-linked | Moderate |
| Superficial peels | Moderate (adjunct) | Operator-dependent | Moderate |
| Low-fluence Nd:YAG laser | Moderate but mixed | Some industry-linked | Low–moderate |
| Microneedling | Weak/mixed | Small studies | Low |
| Picosecond/fractional lasers | Weak (short follow-up) | Often industry-linked | Low |
Sun protection: the non-negotiable base
Nothing below works without this, and the evidence here is some of the strongest in the whole field.
UV light is a primary trigger, but plain sunscreen isn't enough for melasma because visible light — the light you can see, which passes through normal SPF — also drives pigment in deeper skin tones. The fix is a tinted mineral sunscreen containing iron oxides. Iron oxides physically block high-energy visible light, and tinted formulas have been shown to attenuate it by more than 90%.
This isn't just lab data. In a randomized trial, melasma patients using a tinted iron-oxide sunscreen had significantly less worsening of their MASI scores over six months compared with those using a non-tinted sunscreen, despite similar UV protection. The practical takeaway is plain: a broad-spectrum SPF 30 to 50+ tinted mineral sunscreen, reapplied through the day, plus a hat and shade, is the foundation. Skipping it undoes everything else. You can dig into the trial data through this PubMed search on tinted iron-oxide sunscreen and visible light in melasma.
Topical treatments
Creams are first-line for almost everyone. Here's where the evidence is strongest and where it's softer.
Triple combination cream (the gold standard)
Triple combination cream — hydroquinone, a retinoid (tretinoin), and a low-strength corticosteroid (fluocinolone acetonide), sometimes called Kligman's formula — is the most studied and most effective topical treatment for melasma. The evidence-based review found it more effective at lightening melasma than hydroquinone alone, with a relative risk of improvement around 1.6 in pooled data. The three ingredients hit different targets: hydroquinone blocks the enzyme that makes pigment, the retinoid speeds skin turnover and helps the other ingredients penetrate, and the steroid calms irritation.
The downside is that it isn't meant for forever. Long-term daily use can cause irritation, redness, thinning skin, telangiectasias (tiny visible vessels) from the steroid, and — rarely — ochronosis, a paradoxical blue-gray darkening from prolonged hydroquinone use. Most dermatologists use it in cycles: daily for 8 to 12 weeks to clear, then taper to a few nights a week or switch to a non-hydroquinone maintenance plan. You can scan the trial base via this PubMed search on triple combination cream for melasma.
Hydroquinone alone
Hydroquinone at 2% to 4% is the classic single-agent lightener and still works well. It's slightly less effective than the triple cream but avoids the steroid. Same long-term cautions apply: use it in courses, not indefinitely, and watch for ochronosis with prolonged use, especially at higher strengths.
Azelaic acid
Azelaic acid (15% to 20%) is a gentler option that blocks pigment-making enzymes and has mild anti-inflammatory action. The evidence shows 20% azelaic acid performing comparably to 4% hydroquinone in some trials, which is impressive for a non-prescription-strength molecule that's safe in pregnancy. It's a strong pick for sensitive skin and for people who want a hydroquinone alternative. See our azelaic acid for melasma research review for the trial details.
Cysteamine
Cysteamine 5% cream is the most interesting newer entry. It's a non-hydroquinone lightener, doesn't carry the ochronosis risk, and can be used long term. A systematic review and meta-analysis of cysteamine 5% cream concluded it's a reasonable alternative to hydroquinone. But honest grading matters here: in a head-to-head randomized double-blind trial of cysteamine versus hydroquinone, cysteamine reduced MASI less than hydroquinone in the intention-to-treat analysis, though it did much better in people who used it consistently. The smell is unpleasant, which hurts adherence. Bottom line: solid for long-term maintenance and safer than hydroquinone, but probably not stronger.
Tranexamic acid (topical)
Topical tranexamic acid works on the vascular and signaling side of melasma rather than just pigment. The topical evidence is mixed and generally weaker than the oral form, but it's a low-risk add-on. Our tranexamic acid for melasma research review breaks down where it helps.
The supporting cast
Several over-the-counter actives have modest, supportive evidence and are useful for maintenance rather than as a primary fix:
- Niacinamide — reduces pigment transfer; gentle, good for barrier support. Compare it with vitamin C in our niacinamide vs vitamin C evidence review.
- Vitamin C (L-ascorbic acid) — antioxidant that mildly brightens and supports photoprotection.
- Kojic acid and alpha arbutin — enzyme blockers with modest data; see kojic acid vs alpha arbutin for dark spots.
- Tretinoin/retinoids — speed turnover and help other ingredients work; slow on their own.
For a broader OTC comparison, our top 10 at-home hyperpigmentation treatments compared ranks these by evidence.
Topical treatments at a glance
| Treatment | Typical strength | Evidence quality | Effectiveness | Main risk | Long-term use |
|---|---|---|---|---|---|
| Triple combination cream | HQ 4% / tret 0.05% / fluocinolone 0.01% | Strong (multiple RCTs) | Highest | Irritation, telangiectasias, ochronosis | Cycle only |
| Hydroquinone alone | 2–4% | Strong | High | Ochronosis with prolonged use | Cycle only |
| Azelaic acid | 15–20% | Moderate | Moderate–high | Mild stinging | Yes (pregnancy-safe) |
| Cysteamine | 5% | Moderate | Moderate | Odor, irritation | Yes |
| Topical tranexamic acid | 3–5% | Weak–moderate (mixed) | Modest | Mild irritation | Yes |
| Niacinamide | 4–10% | Modest | Modest | Minimal | Yes |
| Vitamin C | 10–20% | Modest | Modest | Mild stinging | Yes |
Oral tranexamic acid
This is the biggest shift in melasma care over the past decade, and the evidence is genuinely good.
Tranexamic acid (TXA) was originally a clotting medication. In melasma, low oral doses appear to calm the overactive signaling between blood vessels, keratinocytes, and melanocytes — addressing the vascular side that creams can't easily reach. A 2024 meta-analysis and systematic review of randomized controlled trials found that oral TXA, typically 250 mg twice daily (about 500 mg/day) for 8 to 12 weeks, produced a clear, statistically significant drop in MASI scores, with effects building through week 12.
The honest caveats: oral TXA can rarely raise clotting risk, so it's avoided in people with a history of blood clots, clotting disorders, smoking plus estrogen use, pregnancy, or certain cancers. It needs a prescription and screening. And melasma often returns after stopping, so it's frequently used in repeated courses alongside topicals and strict sun protection. For most healthy patients, the side-effect profile in trials was mild (bloating, occasional GI upset), but this is a medication, not a supplement. Browse the trial base through this PubMed search on tranexamic acid systematic reviews in melasma.
Chemical peels
Peels can help as an add-on, not usually a standalone cure. Superficial peels — glycolic acid, mandelic acid, salicylic acid, and combinations like the modified Jessner's — remove pigment-laden surface skin and let topicals penetrate better. Evidence supports them as adjuncts to a topical regimen, with results that are modest and operator-dependent.
The key risk in melasma is post-inflammatory hyperpigmentation (PIH): too aggressive a peel can inflame the skin and make pigment worse, especially in darker tones. That's why melasma peels are kept light and spaced out, and why deeper peels (high-concentration TCA, phenol) are generally avoided. Done conservatively by an experienced provider, a series of superficial peels can speed clearing. Done carelessly, they backfire.
A common, sensible protocol is to "prime" the skin with a topical regimen for several weeks before any peel, which both improves results and lowers the PIH risk. Glycolic acid at 20% to 35% and mandelic acid are favored in deeper skin tones because they're gentler and more forgiving. The honest read on the evidence: peels add a modest boost to topicals but rarely outperform a good cream regimen on their own, and the quality of the provider matters more than the specific acid used.
Microneedling
Microneedling has gained popularity for melasma, mostly as a way to deliver topical agents (like tranexamic acid) deeper into the skin and to nudge dermal remodeling. The evidence is limited and mixed — small studies, short follow-up — but some trials show added benefit when microneedling is combined with topical tranexamic acid versus the topical alone. The same PIH caution applies: any procedure that inflames melasma skin can backfire, so settings are kept conservative and the skin is primed first. Treat microneedling as a possible add-on for motivated patients under expert care, not a primary treatment.
Lasers and energy devices
This is the category with the most hype and the most caution flags. Read it carefully.
Lasers can produce dramatic short-term clearing, but melasma is notorious for rebounding after laser treatment, sometimes worse than baseline. The most-studied approach is the low-fluence Q-switched Nd:YAG laser, which uses gentle, repeated passes rather than aggressive energy. A systematic review of low-fluence Q-switched Nd:YAG for melasma found it can improve melasma, and it's popular in Asia, but the same review flagged real risks: roughly 10% of patients in some series developed mottled hypopigmentation (uneven light spots), and rebound darkening is common, particularly in deeper skin tones.
Picosecond lasers and non-ablative fractional lasers (like the 1927 nm thulium) have evidence too, but it's mostly small studies, often industry-linked, with short follow-up. The realistic framing: lasers are a third-line option for melasma that hasn't responded to creams, sun protection, and oral TXA. They should be done by someone who treats a lot of melasma, at conservative settings, always paired with strict photoprotection and topicals. Going in expecting a one-and-done laser fix is the single most common way people make their melasma worse.
Procedure options compared
| Approach | What it does | Evidence | Best role | Key risk |
|---|---|---|---|---|
| Superficial chemical peels | Removes surface pigment, boosts penetration | Moderate (as adjunct) | Add-on to topicals | PIH if too aggressive |
| Microneedling | Improves drug delivery, dermal remodeling | Limited–moderate | Add-on | PIH, irritation |
| Low-fluence QS Nd:YAG laser | Gently fragments pigment over many sessions | Moderate but mixed | Third-line | Hypopigmentation (~10%), rebound |
| Picosecond / fractional lasers | Targets pigment with less heat | Limited, short follow-up | Third-line | Rebound, PIH |
| Deep peels / ablative lasers | Aggressive resurfacing | Avoid | Not recommended | High rebound and scarring risk |
Building a realistic plan
Melasma management is a long game. The structure most dermatologists follow, and the one best supported by the Update on Melasma — Part II: Treatment review, looks like this:
- Foundation, always: Daily tinted mineral (iron-oxide) sunscreen, reapplied, plus hats and shade. This continues forever, even after clearing.
- First line: A topical lightening regimen — triple combination cream or hydroquinone for an active clearing phase of 8 to 12 weeks, then taper.
- Maintenance: Switch to non-hydroquinone topicals (azelaic acid, cysteamine, niacinamide, vitamin C, gentle retinoid) to hold results without the long-term hydroquinone risks.
- Stubborn cases: Add oral tranexamic acid under a prescriber's care after screening for clotting risk.
- Last resort: Conservative chemical peels or low-fluence laser, only with an experienced provider and only on top of the steps above.
Expect slow progress. Meaningful change usually takes 8 to 12 weeks, full results several months, and the patches can fade and return with sun, hormones, and seasons. Managing expectations is part of the treatment.
Special situations
Pregnancy and breastfeeding: "Pregnancy mask" (chloasma) is common and often fades after delivery. During pregnancy, hydroquinone, retinoids, and oral TXA are generally avoided. Safer options are strict sun protection plus azelaic acid, vitamin C, and niacinamide. Talk to your OB or dermatologist before starting anything.
Deeper skin tones: People with Fitzpatrick types IV to VI face the highest risk of PIH and laser-induced hypopigmentation. For these patients, the bias should run heavily toward topicals and photoprotection, with procedures approached very cautiously and conservatively.
Frequently Asked Questions
Can melasma be cured permanently?
No. Melasma is a chronic, relapsing condition. Treatment can fade it dramatically, sometimes to where it's barely visible, but it commonly returns with sun exposure, hormonal changes, or stopping treatment. The realistic goal is long-term control, not a one-time cure, which is why daily sun protection continues even after the patches clear.
What's the single most effective treatment?
For topicals, triple combination cream (hydroquinone, a retinoid, and a corticosteroid) has the strongest evidence and the best results in head-to-head trials. But no single treatment is enough on its own. The most effective real-world plan layers iron-oxide sun protection, a lightening cream, and — for stubborn cases — oral tranexamic acid, because melasma has several drivers at once.
Are lasers a good idea for melasma?
Only as a later option, and only with caution. Lasers can clear melasma fast but are notorious for rebound darkening and, in about 10% of cases with some devices, patchy light spots. They should be a third-line choice after creams, sun protection, and oral tranexamic acid have been tried, done by an experienced provider at gentle settings. Aggressive lasers and deep peels can make melasma permanently worse.
Is hydroquinone safe to use long term?
Not continuously. Hydroquinone is effective but is meant to be used in courses — typically 8 to 12 weeks — then paused or tapered. Prolonged, uninterrupted use can rarely cause ochronosis, a blue-gray darkening that's hard to reverse. Most plans switch to non-hydroquinone maintenance options like azelaic acid, cysteamine, or niacinamide between hydroquinone courses.
How long until I see results?
Plan on patience. Most people start seeing improvement around 8 to 12 weeks of consistent treatment, with fuller results over several months. Melasma fades slowly because pigment that has dropped into the dermis takes a long time to clear. Stopping early, or skipping sun protection, is the most common reason treatment seems to "fail."
The bottom line
The evidence points to a clear hierarchy: iron-oxide sun protection as the unshakable base, topical lightening creams (triple combination or hydroquinone for clearing, then gentler agents for maintenance) as first-line, oral tranexamic acid for stubborn cases under medical supervision, and procedures reserved for last, used conservatively. The treatments with the strongest, most independent evidence are also the safest and least flashy. The flashy ones — aggressive lasers especially — carry the biggest risk of making things worse. Melasma rewards a patient, layered, sun-smart plan over any single magic bullet.
This article is for general education and is not medical advice. Melasma treatment, especially prescription creams, oral medications, and procedures, should be guided by a board-certified dermatologist who can assess your skin type, history, and risk factors.